Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CAMP4 Therapeutics Corporation filings document a clinical-stage biopharmaceutical issuer focused on regulatory RNA-targeting antisense oligonucleotide therapeutics. Its 8-K reports furnish operating results, corporate presentations and program updates for CMP-002 and the company's broader regRNA mapping and ASO discovery work, while material-agreement disclosures describe research, collaboration and license arrangements tied to neurodegenerative and kidney disease targets.
Proxy materials cover board elections, auditor ratification and equity incentive plan matters. Other filings address director appointments, compensatory arrangements, stock-based compensation, capital-structure disclosures, shareholder voting matters and the company’s emerging growth company status.
Camp4 Therapeutics Corp director Douglas E. Williams received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. All 28,000 underlying shares vest together on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, assuming continued service through that date.
Camp4 Therapeutics Corp director Richard A. Young reported receiving a compensation grant of stock options. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.34 per share, expiring on June 9, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, as long as he continues serving the company through that date. After this grant, he holds options for 28,000 shares directly.
Camp4 Therapeutics director and 10% owner Andrew J. Schwab reported receiving a grant of stock options representing 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. According to the footnote, all shares underlying the option vest on the earlier of the first anniversary of the grant date or the issuer's next annual stockholder meeting, contingent on continued service. After this grant, Schwab holds 28,000 options directly.
Camp4 Therapeutics director Steven H. Holtzman received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. All 28,000 options vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues serving the company through that date.
Camp4 Therapeutics Corp director Stewart Murray received a grant of stock options covering 28,000 shares of Common Stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036.
The 28,000 underlying shares vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, provided Murray continues service with Camp4 Therapeutics through that vesting date. Following this grant, his directly held option position reported in this filing is 28,000 options.
Camp4 Therapeutics Corp director and 10% owner Amir Nashat received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $4.34 per share and no cash was paid at grant. They vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, as long as Nashat continues to provide service through that date. After this grant, he holds options for 28,000 shares, which expire on June 9, 2036.
CAMP4 Therapeutics Corporation reported results from its annual meeting and changes to its equity compensation programs. Stockholders approved an amendment to the 2024 Equity Incentive Plan so that any outstanding pre-funded warrants are included in the year-end share count used in the evergreen formula for annual share increases.
The board also adopted a 2026 Inducement Plan allowing various equity awards covering up to 500,000 shares of common stock, to be used as hiring inducements without separate stockholder approval under Nasdaq Listing Rule 5635(c)(4). Stockholders elected three Class II directors, ratified Ernst & Young LLP as auditor for 2026, and approved the equity plan amendment.
Camp4 Therapeutics Corp. Schedule 13G reports that Balyasny Asset Management and related reporting persons may be deemed to beneficially own 2,632,437 shares of common stock, representing approximately 5.07% of the class based on 51,919,321 Shares outstanding as of March 4, 2026. The filing states these holdings arise from positions held by investment vehicles (ADMF and APHC) for which BAM acts as investment manager, and notes 1,624,523 warrants are issuable subject to a Beneficial Ownership Limitation that blocks exercise above 4.99%.
CAMP4 Therapeutics Corporation filed an 8-K to share a corporate update and investor materials highlighting new preclinical data for CMP-002 in SYNGAP1-related disorder. The company presented these findings and an updated slide deck on May 14, 2026.
In a SYNGAP1 haploinsufficient mouse model with chemically induced seizures, a single dose of CMP-002 produced statistically significant improvements in both seizure threshold and seizure severity. These results build on earlier motor and behavioral data, suggesting CMP-002 may address multiple neurological symptoms by restoring SYNGAP1 protein toward healthy levels.
The company describes SYNGAP1-related disorder as a rare central nervous system disease affecting over 10,000 people in the U.S., with high rates of intellectual disability and epilepsy and no approved disease-modifying therapies. CAMP4 expects to advance CMP-002, an antisense oligonucleotide designed to upregulate SYNGAP1, into a global Phase 1/2 clinical trial in the second half of 2026.
CAMP4 Therapeutics Corporation reports first-quarter 2026 results, showing higher collaboration revenue but a wider net loss as it advances its RNA-targeting pipeline. Revenue from research and collaboration grew to $1.3 million, mainly from its agreement with GSK. Research and development expenses were $10.2 million and general and administrative costs $4.2 million, keeping total operating expenses broadly flat versus last year.
The company recorded a non-cash $6.2 million loss from remeasuring its derivative tranche liability linked to a potential second private-placement closing, driving net loss to $18.3 million and basic and diluted net loss per share to $0.32. Operating cash outflow was $11.0 million.
CAMP4 ended the quarter with $99.2 million in cash and cash equivalents and $30.9 million in stockholders’ equity, and believes existing cash will fund operations into 2028. The company is preparing a global Phase 1/2 trial of lead candidate CMP-002 for SYNGAP1-related disorder and continues to leverage its RAP Platform and a $17.5 million GSK collaboration to support future programs.